Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic TSTL
Time: 16:30:05
Mid Price: 59.50
Change Today: -1.00 Descending
Change % Today: -1.65 Descending
Fifty Two Week High: 63.00
Fifty Two Week Low: 36.50
Market Capital: 19.72
Period & price data
Period Price
Now: 59.50
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: AIM
Sector: Healthcare, Equipment & Services
Epic: TSTL
News: Latest news
Web Site: Tristel Plc
Other Articles: 03-07-2009

Tristel Plc

Tristel plc is engaged in the design, manufacture and sale of infection control and water treatment products. The Company’s principal activity include manufacture, development and sale of infection control products using the group’s chlorine dioxide chemistry and its associated applications. Its subsidiaries include Tristel Solutions Limited and Tristel Technologies Limited. The principal activities of the subsidiaries include supply of infection control products.
Friday, July 03, 2009

Tristel buys Medichem infection control portfolio for up to £2.4 mln

company news image

Infection and contamination control company Tristel PLC (AIM: TSTL) said it acquired the intellectual property and manufacturing rights for the portfolio of infection control products manufactured by Medichem International (Manufacturing) Ltd for a at least £2.15 million and up to £2.4 million, depending on future sales.

It also announced a placing of 2,688,287 ordinary shares at 41 pence to raise £1 million net of expenses to pay for part of the acquisition.

The portfolio includes the surface disinfectant product 'TriGene Advance', used in the animal healthcare market. The Medichem portfolio will continue to be distributed by Medichem International (Marketing) Ltd.

Tristel believes that the acquisition is highly complementary to its existing product portfolio which is based on its proprietary chlorine dioxide technology and solely focused on the human healthcare market.

The upfront payment of £1 million will be followed by cash payments over five years depending on the annual sales generated from the Medichem product portfolio.

The Medichem product portfolio generated sales in the year to December 31 2008 of £2.06 million. Tristel expects the acquisition to be earnings enhancing in its financial year commencing July 1 2009, although the transfer of production to its Newmarket   manufacturing facility will be phased in gradually over the first half of the financial year.

Tristel established its manufacturing facility in 2007 to enable it to take over from Medichem the production of its chlorine dioxide products.

NewsNow icon AddThis Feed Button
Register here to be notified of future Tristel Plc articles.

Other Tristel Plc news

More news ►

Investors interested in Tristel Plc recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.